Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment

References

• Barbone FP, Johnson DL, Farrell FX, et al. New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 1999;14(Suppl 2):80–4
   PubMed Web of Science ®Google Scholar
• Downey P. Recombinant human erythropoietin as a treatment for anemia of prematurity. J Perinat Neonatal Nurs 1997;11:57–68
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649–59
   PubMed Web of Science ®Google Scholar
• Levin A. Identification of patients and risk factors in chronic kidney disease – evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001;16(Suppl 7):57–60
   PubMedGoogle Scholar
• Monnerat C, Leyvraz S. Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia [in German]. Schweiz Rundsch Med Prax 1999;88:178–88
   Google Scholar
• Levin A. How should anaemia be managed in pre-dialysis patients? Nephrol Dial Transplant 1999;14(Suppl 2):66–74
   PubMedGoogle Scholar
• Linde T, Sandhagen B, Wikstrom B, Danielson BG. The required dose of erythropoietin during renal anaemia treatment is related to the degree of impairment in erythrocyte deformability. Nephrol Dial Transplant 1997;12:2375–9
   PubMed Web of Science ®Google Scholar
• Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24:777–84
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73–8
   PubMed Web of Science ®Google Scholar
• Sunder-Plassmann G, Patruta SI, Horl WH. Pathobiology of the role of iron in infection. Am J Kidney Dis 1999;34(4 Suppl 2):S25–9
   Google Scholar
• Adamson JW, Eschbach JW. Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q J Med 1989;73:1093–101
   PubMedGoogle Scholar
• Muirhead N, Hodsman AB. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. Nephrol Dial Transplant 1990;5:232–4
   PubMed Web of Science ®Google Scholar
• Caro JJ. Anemia of chronic renal failure. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams' Hematology, 5th edn. New York: McGraw-Hill, 1995:456–62
   Google Scholar
• Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53–61
   PubMed Web of Science ®Google Scholar
• Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347–54
   PubMed Web of Science ®Google Scholar
• Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000;15:650–8
   PubMed Web of Science ®Google Scholar
• Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 2002:35–8
   PubMedGoogle Scholar
• Raftery MJ, Auinger M, Hertlova M. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Collaborative Study Group. Clin Nephrol 2000;54:240–5
   Google Scholar
• Ritz E, Eisenhardt A. Early epoetin treatment in patients with renal insufficiency. Nephrol Dial Transplant 2000;15(Suppl 3):40–4
   PubMedGoogle Scholar
• Janatpour K, Holland PV. Noninfectious serious hazards of transfusion. Curr Hematol Rep 2002;1:149–55
   PubMedGoogle Scholar
• House AA, Pham B, Page DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant 1998;13:1763–9
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–84
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085–98
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Public statement: epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risk in patients with chronic kidney disease. Available at: http://wwwemeaeuropaeu [Last accessed 2 January 2008]
   Google Scholar
• Food and Drug Administration (FDA). Information for healthcare professionals: erythropoiesis stimulating agents (ESA). Available at: http://wwwfdagov/drug/Infosheets/HCP/RHE2007HCPhtm [Last accessed 2 January 2008]
   Google Scholar
• Portoles J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541–8
   PubMed Web of Science ®Google Scholar
• Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353–61
   PubMed Web of Science ®Google Scholar
• Ross SD, Fahrbach K, Frame D, et al. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003;25:1786–805
   PubMed Web of Science ®Google Scholar
• McMahon LP, McKenna MJ, Sangkabutra T, et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999;14:1182–7
   PubMed Web of Science ®Google Scholar
• Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122–30
   PubMed Web of Science ®Google Scholar
• Wu SC, Lin SL, Jeng FR. Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients. Scand J Urol Nephrol 2001;35:136–40
   PubMedGoogle Scholar
• World Health Organization (WHO). WHO Informal Consultation on International Nonproprietary Names (INN) Policy for Biosimilar Products. Geneva, Switzerland: WHO, 2006. Available at: http://www.who.int/medicines/services/inn/BiosimilarsINN_ReportSept2006.pdf [Last accessed 30 November 2007]
   Google Scholar
• European Medicines Agency (EMEA). Questions and answers on biosimilar medicines (similar biological medicinal products). London: EMEA, 2007. Available at: http://www.emea.europa.eu/pdfs/human/pcwp/7456206en.pdf [Last accessed 30 November 2007]
   Google Scholar
• European Generic Medicines Agency. Frequently asked questions about biosimilar medicines. Available at: http://www.egagenerics.com/FAQ-biosimilars.htm [Last accessed 2 January 2008]
   Google Scholar
• European Association for Bioindustries (EuropaBio). Biological and biosimilar medicines. Brussels: EuropaBio, 2005. Available at: http://www.europabio.be/documents/FS-Biosimilar.pdf [Last accessed 30 November 2007]
   Google Scholar
• European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. CHMP/437/04. EMEA 2005. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/043704en.pdf [Last accessed 30 November 2007]
   Google Scholar
• European Directorate for the Quality of Medicines & Healthcare (EDQM). The European Pharmacopoeia, 6th edn. Strasbourg: EDQM, 2007
   Google Scholar
• Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19\(Suppl 2):ii1–47
   Google Scholar
• Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469–75
   PubMed Web of Science ®Google Scholar
• Casadevall N, Dupuy E, Molho-Sabatier P, et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630–3
   Google Scholar
• Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 2002;17(Suppl 5):42–7
   PubMed Web of Science ®Google Scholar
• Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67:2346–53
   PubMed Web of Science ®Google Scholar
• Schellekens H. Lesson learned from Eprex-associated pure red cell aplasia. Kidney Blood Press Res 2007;30(Suppl 1):9–12
   PubMedGoogle Scholar
• Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992–1000
   PubMed Web of Science ®Google Scholar
• Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741–7
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Korbet S, Faber M, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995;5:1517–29
   PubMed Web of Science ®Google Scholar